Times Square Capital Management, LLC Vaxcyte, Inc. Transaction History
Times Square Capital Management, LLC
- $6.49 Billion
- Q3 2024
A detailed history of Times Square Capital Management, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Times Square Capital Management, LLC holds 269,121 shares of PCVX stock, worth $23.4 Million. This represents 0.47% of its overall portfolio holdings.
Number of Shares
269,121Holding current value
$23.4 Million% of portfolio
0.47%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
351Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$993 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$948 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$863 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$754 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$425 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.15B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...